



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Books

Search PubMed



for

 Limits

Preview/Index

History

Clipboard

Details



About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation

Matcher

Batch Citation

Matcher

Clinical Queries

LinkOut

Cubby

Related

Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

1: J Immunol Methods. 1988 Jul 22;111(2):271-5. Related Articles, Links

The immunochemistry of sandwich-ELISAs. IV. The antigen capture capacity of antibody covalently attached to bromoacetyl surface-functionalized polystyrene.

Peterman JH, Tarcha PJ, Chu VP, Butler JE.

Department of Microbiology, University of Iowa, Iowa City 52242.

The antigen capture capacity of antibodies covalently immobilized on injection-molded polystyrene beads was evaluated. Bromoacetyl groups on the bead surfaces rendered them reactive to protein nucleophilic groups. The bromoacetyl surface exhibited up to a ten-fold greater capacity for protein compared to unmodified polystyrene, with no detectable dissociation such as occurs with simple adsorption. Biotinylated anti-fluorescein was immobilized on this surface both through direct covalent attachment and indirectly via streptavidin, which was first covalently attached to the bead. Comparisons of the resulting biological activity, normalized to the amount of anti-fluorescein on the bead, were made between the attachment methods and simple passive adsorption. The presence of the streptavidin spacer on the bromoacetyl surfaces improved the antigen capture capacity of antifluorescein, for fluoresyl-albumin by 45% compared to direct covalent linkage of the antibody to modified polystyrene and by 160% relative to antibody adsorbed on unmodified polystyrene.

PMID: 3397550 [PubMed - indexed for MEDLINE]

 Display

Abstract



Show: 20



Sort



Send to



[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)

Aug 6 2003 12:56:11



PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books

Search for

Limits Preview/Index History Clipboard Details

About Entrez

Show:

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation

Matcher

Batch Citation

Matcher

Clinical Queries

LinkOut

Cubby

Related

Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

1: J Immunoassay. 1986;7(1-2):113-28.

Related Articles, Links

An enzyme-linked immunosorbent assay for the antineoplastic agent vincristine.

Lapinjoki SP, Verajankorva HM, Huhtikangas AE, Lehtola TJ, Lounasmaa M.

An enzyme-linked immunosorbent assay for vincristine was developed, based on a new procedure for synthesizing the hapten-protein conjugate. In both the immunogen and the enzyme tracer a spacer group was introduced between the hapten and protein, and the vincristine was coupled at a site far from its functional groups. The antibody produced proved to be exceptionally specific as compared with previous immunoassays for bis-indole alkaloids. Thousandfold antibody dilutions could be used and samples at the femtomole range were assayable. Applications of the method to patient plasma samples and to plant material are described.

PMID: 3734107 [PubMed - indexed for MEDLINE]

Show:

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)

Aug 6 2003 12:56:11



PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books

Search for

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation

Matcher

Batch Citation

Matcher

Clinical Queries

LinkOut

Cubby

Related

Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

[1]: Biol Chem Hoppe Seyler. 1991 Mar;372(3):163-72.

Related Articles, Links

Enzyme immunoassay with captured hapten. A sensitive gastrin assay with biotinyl-gastrin derivatives.

von Grunigen R, Siglmuller G, Papini A, Kocher K, Traving B, Gohring W, Moroder L.

Max-Planck-Institut fur Biochemie, Abteilung Peptidchemie, Martinsried, Germany.

Two N-terminal biotinyl-gastrin derivatives were synthesized to investigate the effect of the length and chemical properties of the biotin-spacer on both the capture of the hapten by streptavidin or avidin adsorbed on polystyrene, and the antigenicity of the captured peptide. The observed full retention of antibody binding capacity of the biotinyl-gastrins upon their immobilization, allowed to develop a sandwich-type ELISA with a sensitivity of one order of magnitude better than the standard ELISA with polystyrene-adsorbed gastrin. This hapten capture system reduces desorption particularly pronounced for low mass peptides, and avoids possible modifications or suppression of epitopes by the adsorption process with concomitant reduction of antibody binding affinity of the antigen. This new type of assay procedure may also represent a useful tool particularly for epitope mapping with relatively low mass synthetic protein fragments.

PMID: 2054095 [PubMed - indexed for MEDLINE]

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)

Aug 6 2003 12:56:11



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Books

Search for  Limits

Preview/Index

History

Clipboard

Details

About Entrez



Abstract



Show: 20



Text



Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation

Matcher

Batch Citation

Matcher

Clinical Queries

LinkOut

Cubby

Related

Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

 1: Mol Immunol. 1984 Nov;21(11):1055-60.

Related Articles, Links

Immunogenicity of biotinylated hapten-avidin complexes.

Scott D, Nitecki DE, Kindler H, Goodman JW.

The efficacy of avidin as a carrier for the generation of anti-hapten antibodies was assessed in mice by immunization with complexes of avidin and synthetic peptides containing biotin and an epsilon-dinitrophenyl (DNP) lysine residue. The synthetic haptens were constructed with 0, 1 or 2 6-aminocaproyl groups as spacers between the biotin and DNP-lysine moieties. Complexes without a spacer did not induce anti-DNP antibody responses, while those with two spacers induced stronger responses than those with only one spacer. However, the anti-DNP responses to avidin-biotinylated hapten complexes were considerably weaker than responses to a conventional hapten-protein conjugate (DNP-ovalbumin), and, like "T-independent" antigens, failed to induce significant immunological memory. The distribution of isotypes in the anti-DNP antibodies produced to avidin-biotin-6-aminocaproyl-epsilon-DNP-lysine-alanine and DNP-ovalbumin was similar, but the former antigen induced significantly lower levels of antibody in (CBA/N X BALB/c) F1 male mice with the xid defect than in phenotypically normal female littermates, and also induced significant responses in nu/nu mice, in contrast to DNP-ovalbumin. These findings suggest that there is at least a "T-independent" or "T-efficient" component in the response to avidin-biotin complexes, perhaps due to the tetrameric structure of the molecule. Estimates of the depth of the receptor site for biotin were obtained by using the complexes to competitively inhibit the binding of anti-DNP antibody to plates coated with DNP-protein. The findings were consonant with the data on immunogenicity (capacity to induce anti-DNP antibody responses) and suggested that the receptor site has a depth of 16-26 Å.

PMID: 6440008 [PubMed - indexed for MEDLINE]



Abstract



Show: 20



Text



[Write to the Help Desk](#)

A recombinant, soluble, single-chain class I major histocompatibility complex molecule with biological activity

(H-2D^d/β₂-microglobulin/antigen presentation)

MICHAEL G. MAGE*, LI LEE*, RANDALL K. RIBAUDO†, MARIPAT CORR†, STEVEN KOZLOWSKI†,
LOUISE MCHUGH*, AND DAVID H. MARGULIES†

*Laboratory of Biochemistry, National Cancer Institute, and †Molecular Biology Section, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892

Communicated by Elvin A. Kabat, July 31, 1992

ABSTRACT Heterodimeric class I major histocompatibility complex molecules, which consist of a 45-kDa heavy-chain and a 12-kDa β₂-microglobulin (β₂m) light chain, bind endogenously synthesized peptides for presentation to antigen-specific T cells. We have synthesized a gene encoding a single-chain, soluble class I molecule derived from mouse H-2D^d, in which the carboxyl terminus of β₂m is linked via a peptide spacer to the amino terminus of the heavy chain. The chimeric protein is secreted efficiently from transfected L cells, is thermostable, and when loaded with an appropriate antigenic peptide, stimulates an H-2D^d-restricted antigen-specific T-cell hybridoma. Thus, functional binding of peptide does not require the complete dissociation of β₂m, implying that a heavy chain/peptide complex is not an obligate intermediate in the assembly of the heavy-chain/β₂m/peptide heterotrimer. Single-chain major histocompatibility complex molecules uniformly loaded with peptide have potential uses for structural studies, toxin or fluor conjugates, and vaccines.

Balanced production of naturally multimeric proteins (such as antibodies) can be facilitated by engineering them as single-chain molecules (1–3). Such a strategy links the structural domains so they cannot dissociate and may be an initial step to the production of toxin conjugates and large-scale synthesis in bacteria. Analysis of the kinetics and thermodynamics of folding, domain interaction, and ligand binding by such tethered molecules may also provide insight into the conformational changes that accompany these events. Because the heterodimeric major histocompatibility complex (MHC) class I molecules play an important role in immune responses, we have engineered a single-chain MHC class I molecule, in which the immunoglobulin domain-like subunit β₂-microglobulin (β₂m) is linked via a peptide spacer to the amino terminus of the peptide-binding H-2D^d heavy chain (SCβD^d). A similar approach, in which the carboxyl terminus of the extracellular portion of a truncated H-2K^d heavy chain was linked to the amino terminus of β₂m through a spacer, has been reported (4), but those molecules were neither expressed efficiently nor secreted and were not shown to function in the activation of T cells.

The class I MHC molecules, synthesized by and expressed on the surfaces of most vertebrate cells, consist of a 45-kDa heavy chain, noncovalently associated with a 12-kDa light chain, β₂m. These MHC class I molecules bind peptides derived from endogenously synthesized self- (5) or pathogen-encoded proteins (6–9) and display them for recognition by T lymphocytes through their αβ antigen-specific T-cell receptors. The β₂m chain plays an important role in MHC class I intracellular transport (10–12), peptide binding (13–18), and

conformational stability (12, 19–22). For most class I molecules, a heterotrimer consisting of the MHC class I heavy chain, self- or antigenic peptide, and β₂m is required for biosynthetic maturation and cell-surface expression (16, 17, 23).

The order of assembly of the heterotrimer is not known. There are data consistent with (i) heavy chain first binding to β₂m and the complex then binding peptide or (ii) heavy chain first binding peptide and the complex then being stabilized by β₂m (24, 25). We hypothesized that studies of single-chain molecules in which β₂m was covalently tethered to the class I heavy chain might help determine whether normal formation of the ternary complex requires a heavy chain/peptide intermediate, or whether a heavy chain/β₂m complex can form and then bind peptides.

MATERIALS AND METHODS

Antibodies. Hybridomas producing monoclonal antibody (mAb) 34-5-8, which binds to a conformationally labile and peptide-dependent epitope of the α₁α₂ domain of H-2D^d, and mAb 34-2-12, which binds to a more stable and peptide-independent epitope of the α₃ domain (22, 26, 27), were from American Type Culture Collection. Polyclonal antibodies to H-2D^d heavy chain (322-1) and to murine β₂m (322-3) were produced by immunizing rabbits with denatured heavy chain and β₂m, respectively. The anti-heavy-chain antibody has a preference for free heavy chains and precipitates little or no heterodimeric heavy chain/β₂m complex.

Construction of the Single-Chain β₂m/H-2D^d Molecule. Genes for β₂m and class I MHC heavy chain were linked so as to connect the carboxyl terminus of β₂m to the amino terminus of the heavy chain via a peptide spacer. The length of the spacer needed was measured on a three-dimensional computer graphic model of the H-2D^d murine β₂m heterodimer, based on the high-resolution crystallographic coordinates (Brookhaven Protein Data Bank no. 3hla) of the human class I molecule HLA-A2 (28), by amino acid substitution and multiple rounds of energy minimization using QUANTA version 3.0 (Polygen, Waltham, MA). These measurements indicated that a 15-amino acid peptide spacer consisting of the sequence (GGGGS)₂ (29) would allow β₂m to find its normal position relative to the heavy chain. The β₂m-encoding gene was amplified by PCR from a cDNA clone (pβ2m.1), which was constructed from a cDNA library derived from C57BL/6 mouse liver. Its structure was confirmed by DNA sequencing (R.K.R. and D.H.M., unpublished work). We used a 5'-sense primer 3504 (TGG GTC GAC ATG GCT CGC TCG GTG ACC CTG) containing the sequence for a Sal I site immediately 5' to the signal peptide

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Abbreviations: MHC, major histocompatibility complex; β₂m, β₂-microglobulin; H-2D^d, soluble analogue of H-2D^d; SCβD^d, soluble single-chain class I MHC molecule that contains β₂m/spacer/H-2D^d.

sequence and a 3' antisense primer 3505 (GCC GCC ACC CGA GCC GCC TCC GCC CGA ACC GCC ACC TCC CAT GTC TCG ATC CCA GTA GAC) containing the sequence for the 3' end of β_2m and for a portion of the peptide spacer. The heavy-chain gene was PCR-amplified from a plasmid containing cDNA encoding a soluble form of H-2D d (H-2D s) consisting of the α_1 , α_2 , and α_3 H-2D d domains and the 27 carboxyl-terminal amino acid residues of Q10 b (14), using a 5' sense primer 3506 (GGC GGC TCG GGT GGC GGC GGC TCT GGC GGA GGT GGA TCC GGC TCA CAC TCG CTG AGG) encoding a portion of the peptide spacer, an overlap to the 3' primer of β_2m , sequence for the 5' end of the H-2D d gene, and a 3' antisense primer 3507 (ACT AAG CTT CAC TGG AGC GGG AGC ATA GTC) containing H-2D d 3'-untranslated region sequence and a HindIII site. The two PCR products were mixed and spliced by overlap extension (30), using the 5' primer for β_2m and the 3' primer for H-2D d . The PCR product was purified, cut with Sal I and HindIII, repurified, and ligated into a eukaryotic expression vector pH β APr-1 neo (31) by standard methods. DNA sequencing revealed three point mutations, probably PCR-induced, which were corrected by site-directed mutagenesis using the Altered Sites kit from Stratagene. The corrected SC β D s clone (for a soluble single-chain class I MHC molecule that contains β_2m /spacer/H-2D d) was sequenced in its entirety with Sequenase 2 (United States Biochemical).

Transfection. DAP-3 cells were exposed to DNA precipitated with calcium phosphate (32). Transformants were selected with the antibiotic G418 and cloned by limiting dilution.

ELISA of Secreted Class I Proteins. Immulon 4 (Dynatech) 96-well flat-bottom plates (precoated with an affinity-purified hamster anti-mouse H-2 antibody GBH6) were incubated overnight at 4°C with culture supernatants, washed, and treated sequentially with either mAb 34-2-12 or mAb 34-5-8, followed by alkaline phosphatase-conjugated rat anti-mouse immunoglobulin (14). Molar concentrations were calculated relative to a reference preparation of affinity-purified two-chain H-2D d . All values are mean \pm SEM of three determinations.

Radiolabeling and Immunoprecipitation of Cells. Transfected DAP-3 cells in 24-well plates were pulsed for 16 hr with 900 μ Ci of [35 S]methionine per ml (1 Ci = 37 GBq). Culture supernatants were precleared with normal rabbit serum, and aliquots were then incubated with antibody, followed by protein A-Sepharose beads. Washed beads were boiled with 2% SDS/0.35 M 2-mercaptoethanol, and supernatants were analyzed by PAGE and fluorography (33).

Immunoblotting. Soluble single-chain class I MHC molecules (from SC β D s clone) were affinity-purified at 4°C by passing culture supernatants through a column of mAb 34-2-12 coupled to Sepharose 4B and eluting with carbonate buffer (0.15 M NaCl/0.15 M Na₂CO₃) at pH 11.5. Fractions (1.0 ml) were collected in tubes containing 0.25 ml of 2 M Tris-HCl, pH 7.6, to get prompt neutralization. The purified SC β D s and soluble two-chain H-2D d were electrophoresed after denaturation and reduction on a 20% Phast Gel (Pharmacia) under denaturing conditions and blotted onto nitrocellulose. The blot was blocked with 1% dry milk, incubated with rabbit anti- β_2m (322-3), and developed with 125 I-labeled protein A (Amersham).

T-Cell Stimulation Assays. Affinity-purified single-chain SC β D s or two-chain H-2D d molecules were coated onto a Dynatech Immulon 4 plate at 5 μ g/ml for 2-3 hr at 27°C. Both the single-chain and two-chain molecules were purified from cell culture supernatants containing fetal calf serum. Two-chain H-2D d , grown under these conditions, has a limited dependence on exogenous β_2m (S.K. and D.H.M., unpublished work). After washing with phosphate-buffered saline, the plates were blocked for 2 hr at 37°C with 1% fetal calf

serum/Dulbecco's modified Eagle's medium, washed again, and incubated overnight at 37°C with peptide p18I10 (Arg-Gly-Pro-Gly-Arg-Ala-Phe-Val-Thr-Ile) from human immunodeficiency virus III_B glycoprotein 120 envelope (ref. 34; T. Takeshita, S.K., R. D. England, R. Brower, H. Takahashi, C. DeLisi, C. D. Pendleton, D.H.M., and J. A. Berzofsky, personal communication) dissolved in phosphate-buffered saline. After three more washes, 2 \times 10⁴ B4.2.3 T-hybridoma cells (14) in 200 μ l of Dulbecco's modified Eagle's medium/10% fetal calf serum/2 mM glutamine/nonessential amino acids/gentamycin at 50 μ g/ml/50 μ M 2-mercaptoethanol were added to each well. Plates were again incubated overnight at 37°C. The next day the cells were pulsed with 1 μ Ci of [3 H]thymidine and harvested; incorporated label was counted after a further 6 hr at 37°C. Percent inhibition of growth was calculated as [(cpm of T-hybridoma cells in the presence of peptide and purified H-2D d) \div (cpm of T-hybridoma cells in the absence of peptide with purified H-2D d)] \times 100.

RESULTS

Construction and Expression of a Gene Encoding a Single-Chain Class I Molecule. We designed our construct to encode β_2m amino terminal to H-2D d , linked via an amino acid spacer, so that the synthesis and folding of the compact, immunoglobulin-like domain structure of β_2m would precede that of the heavy chain (Fig. 1). We prepared the chimeric gene from a β_2m cDNA clone and H-2D d (14) by using PCR and splicing by overlap extension (30). The *in vitro* recombinant gene fragment SC β D s , encoding the β_2m leader peptide, the β_2m coding block, a 15-amino acid residue spacer, and the H-2D d coding block was cloned in a vector (pH β APr-1 neo) under control of the human β -actin promoter (31). The resultant recombinant plasmid (pSC β D s 15), encoding a single-chain molecule (hereafter called SC β D s) with covalently linked β_2m and H-2D d sequences, was used to stably transfet the murine L cell line DAP-3 (32).

We examined cultures of transfected DAP-3 cells for secretion of SC β D s with a capture ELISA assay and detected material that reacted with mAb 34-5-8, which binds an epitope of the $\alpha_1\alpha_2$ domain unit, as well as with mAb 34-2-12, which sees the α_3 domain (26, 27). Concentrations of up to 1 \times 10⁻⁸ M (0.6 μ g/ml) per week accumulated in the supernatant (Fig. 2A), and the SC β D s protein was affinity-purified (33). The relative ratio of mAb 34-5-8 to mAb 34-2-12 epitope for SC β D s was higher than that of the heterodimeric H-2D d , indicating that correctly folded molecules were being secreted (Fig. 2B) and that the $\alpha_1\alpha_2$ domain of the SC β D s molecules may be more conformationally homogeneous than in two-chain H-2D d molecules. This higher ratio may reflect a greater proportion of correctly folded molecules in the SC β D s preparation. Secreted SC β D s was thermally stable (Fig. 2C). This result suggested that it had bound endogenous peptides, inasmuch as "empty" class I MHC molecules are unstable at 37°C (22, 35).

SDS/PAGE Analysis of SC β D s . Having found that correctly folded SC β D s molecules were being secreted, we confirmed that the SC β D s was a single-chain product of the recombinant gene by metabolically labeling SC β D s -secreting cells with [35 S]methionine and analyzing culture supernatants by immunoprecipitation and SDS/PAGE. We found a radio-labeled protein with a relative molecular mass under reducing conditions of \approx 56 kDa that was immunoprecipitated by a polyclonal rabbit anti-H-2 antiserum 322-1 and by both the anti- α_3 domain 34-2-12 and the anti- $\alpha_1\alpha_2$ domain 34-5-8 mAbs (Fig. 3, single chain, lanes A-C, respectively). Unlike the two-chain H-2D d molecule in which the mAbs coprecipitated the 12-kDa β_2m light chain with the heavy chain (Fig. 3, two chain, lanes B and C), the SC β D s protein showed no copre-




FIG. 1. Map and diagram of the single-chain $\text{SC}\beta\text{D}_s^d$ construct. Splicing by overlap extension (30) was used to link the genes so as to connect the carboxyl terminus of $\beta_2\text{m}$ to the amino terminus of the $\text{H}-2\text{D}_s^d$ heavy chain via a peptide spacer. Also shown are the restriction sites for insertion into the polylinker of $\text{pH}\beta\text{APr-1 neo}$ (βApr) (31).

cipitating $\beta_2\text{m}$. The difference in size of ≈ 14 kDa between the $\text{SC}\beta\text{D}_s^d$ and the $\text{H}-2\text{D}_s^d$ heavy chain is consistent with the expected molecular mass of $\beta_2\text{m}$ (12 kDa) plus the 15-amino acid peptide spacer (1.3 kDa). The material that is smaller than 30 kDa (lane B) appears to be an $\text{H}-2\text{D}^d$ fragment containing the α_3 domain epitope but has not been further characterized. The decreased ability of the anti- α_3 domain mAb to coprecipitate $\beta_2\text{m}$ has been observed consistently (27).

To verify the covalent linkage of $\beta_2\text{m}$ to the heavy-chain, affinity-purified $\text{SC}\beta\text{D}_s^d$ was analyzed by SDS/PAGE under reducing conditions (Fig. 4A) and by immunoblotting (Fig. 4B). SDS/PAGE analysis revealed a major band of ≈ 56 kDa (Fig. 4A, lane 1) and little or no copurifying $\beta_2\text{m}$ light chain. This result contrasts with the $\text{H}-2\text{D}_s^d$ molecule, which has a heavy chain of 37 kDa associated with the 12-kDa $\beta_2\text{m}$ light chain (Fig. 4B, lane 2). Immunoblot analysis of a similar gel

using a rabbit anti- $\beta_2\text{m}$ polyclonal antibody (Fig. 4B) revealed that the $\text{SC}\beta\text{D}_s^d$ 56-kDa band contained $\beta_2\text{m}$ (Fig. 4B, lane 1), whereas only the 12-kDa $\beta_2\text{m}$ band of the two-chain molecule reacted with the antibody (lane 2). Thus, the secreted protein product of the $\text{SC}\beta\text{D}_s^d$ gene contains $\beta_2\text{m}$ epitopes in a molecule of the anticipated size.

In Vitro Peptide Antigen Presentation by $\text{SC}\beta\text{D}_s^d$. To test for biological activity as an antigen-presenting molecule, affinity-purified $\text{SC}\beta\text{D}_s^d$ was pulsed with a synthetic peptide, p18I10, known to be $\text{H}-2\text{D}^d$ -restricted (34) and tested for the




FIG. 2. $\text{SC}\beta\text{D}_s^d$ protein secretion, folding, and thermostability. Cell culture supernatants were evaluated for mAb epitopes by ELISA as described. (A) Secretion rate, $M \times 10^{-9}$ per week. (B) Relative ratio of $\alpha_1\alpha_2$ epitope (mAb 34-5-8) to α_3 epitope (mAb 34-2-12) normalized to 1 for $\text{H}-2\text{D}^d$. (C) Percent of mAb 34-5-8 epitope remaining after 45 min at 53°C. □, Single-chain (1 CH) $\text{SC}\beta\text{D}_s^d$; ■, two-chain (2 CH) $\text{H}-2\text{D}^d$.




FIG. 3. $\text{SC}\beta\text{D}_s^d$ is a secreted protein of 56 kDa without separable $\beta_2\text{m}$. Radiolabeled culture supernatants were precipitated with rabbit antibody to $\text{H}-2\text{D}^d$ heavy chain (mAb 322-1) (A); mAb 34-2-12 (anti- α_3) (B); mAb 34-5-8 (anti- $\alpha_1\alpha_2$) (C); or no antibody (D). Molecular mass markers are given in kDa. (Left) Single-chain $\text{SC}\beta\text{D}_s^d$. (Right) Two-chain $\text{H}-2\text{D}^d$.




FIG. 4. Affinity-purified $\text{SC}\beta\text{D}_4^d$ is not associated with natural $\beta_2\text{m}$ but contains $\beta_2\text{m}$ epitopes. Affinity-purified $\text{SC}\beta\text{D}_4^d$ (lanes 1) and affinity-purified soluble two-chain H-2D d (lanes 2) were electrophoresed after denaturation and reduction and analyzed by staining with Coomassie brilliant blue (A) or by immunoblotting with rabbit anti- $\beta_2\text{m}$ (322-3) and developed with ^{125}I -labeled protein A (B) as described.

ability to stimulate an antigen-specific H-2D d -restricted T-cell hybridoma that responds to the antigen/MHC complex by growth inhibition (14). As shown in Fig. 5, $\text{SC}\beta\text{D}_4^d$ molecules effectively presented the peptide antigen to this hybridoma in a dose-dependent fashion. On the order of 10- to 100-fold higher peptide concentrations were needed to provide T-cell stimulation with $\text{SC}\beta\text{D}_4^d$ compared with the two-chain H-2D d molecule. This result would be expected if, with tethered $\beta_2\text{m}$, the bound endogenous peptides were less able to dissociate and exchange with added antigenic peptides. It is possible that the single-chain molecules are not folded identically to the native molecule, and the T cells detect some subtle differences not detected by the conformationally sensitive antibody.

DISCUSSION

These data indicate the successful biosynthesis and secretion in stably transfected L cells of a T-cell stimulatory recom-




FIG. 5. Antigen presentation by $\text{SC}\beta\text{D}_4^d$, as measured by growth inhibition. Affinity-purified single-chain $\text{SC}\beta\text{D}_4^d$ (\circ , 1 CH) or two-chain H-2D d (\bullet , 2 CH) molecules (33) were coated onto a microtiter plate and incubated with p18110 at concentrations shown. After addition of B4.2.3 cells and incubation overnight, the cells were pulsed with [^3H]thymidine and harvested; radioactivity of incorporated label was then counted. Percent inhibition was calculated, and values plotted are means \pm SEM of percent inhibition, calculated from triplicate wells. In absence of peptide, cpm were 170,000 for H-2D d and 230,000 for $\text{SC}\beta\text{D}_4^d$. With a control H-2L d -restricted peptide YPHFMPTNL (36) at 1×10^{-5} M, cpm were 210,000 for H-2D d and 240,000 for $\text{SC}\beta\text{D}_4^d$.

binant soluble single-chain class I MHC molecule $\text{SC}\beta\text{D}_4^d$. Correct folding is indicated by the presence of both the $\alpha_1\alpha_2$ and α_3 domain epitopes detected by ELISA (Fig. 2) and by immunoprecipitation (Fig. 3). The single-chain nature is confirmed by the presence of a 56-kDa band that reacts with antibodies to both H-2D d (Fig. 3) and $\beta_2\text{m}$ (Fig. 4). The functional ability of the single-chain molecule to react with a human immunodeficiency virus envelope glycoprotein 160-specific, H-2D d -restricted T-cell hybridoma indicates that the antigenic peptide is bound in the same configuration as in the wild-type two-chain H-2D d . The molecule described here, in contrast to that of Mottez *et al.* (4), has the opportunity to fold its rigid immunoglobulin-like $\beta_2\text{m}$ domain first, providing a local high concentration of $\beta_2\text{m}$ for the covalently linked H-2D d and allowing $\beta_2\text{m}$ to play its critical role in the formation of a structure available for peptide binding (13, 18, 21, 22). The thermostability and high mAb 34-5-8/mAb 34-2-12 ratio of $\text{SC}\beta\text{D}_4^d$ (Fig. 2) suggest that self-peptides are effectively complexed to these molecules. Preliminary data indicate that endogenous peptides can be eluted from $\text{SC}\beta\text{D}_4^d$ and that they seem to have the same sequence motif as the two-chain H-2D d (M.M. and M.P.C., unpublished data). This result, in turn, indicates that a $\beta_2\text{m}$ -free heavy-chain/peptide complex is not an obligate intermediate in the assembly of the heterotrimer and that $\text{SC}\beta\text{D}_4^d$, despite $\beta_2\text{m}$ being tethered, allows sufficient flexibility for peptide binding.

We have demonstrated that synthesis, folding, and secretion of a single-chain class I MHC molecule with functional activity occurs in a mammalian cell line. Whether the synthesis of similar single-chain class I MHC molecules can be accomplished in other expression systems awaits determination; this work has been done for the two-chain class I molecules in baculovirus (37) and bacteria (38, 39). Further modification of the single-chain constructs could include the incorporation of toxin moieties and covalently linked antigenic peptide sequences. Such molecules offer potential for uniform peptide-loaded preparations for structural studies (39, 40) and might serve as components of vaccines, of toxin conjugates for killing autoimmune or malignant T cells, or of specifically labeled reagents for the imaging of specific T-cell clones.

We thank our colleagues J. Berzofsky, W. Biddison, D. Fitzgerald, R. Germain, and K. Ozato for their suggestions and comments on the

manuscript, and T. Takeshita, C. D. Pendleton, and J. Berzofsky for the human immunodeficiency virus III_B glycoprotein 120-derived peptide. R.K.R. is a fellow of the National Multiple Sclerosis Society and of the Cancer Research Institute.

1. Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S. M., Pope, S. H., Riordan, G. S. & Whitlow, M. (1988) *Science* **242**, 423–426.
2. Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M.-S., Novotny, J., Margolies, M. N., Ridge, R. J., Brucolieri, R. E., Haber, E., Crea, R. & Oppermann, H. (1988) *Proc. Natl. Acad. Sci. USA* **85**, 5879–5883.
3. Winter, G. & Milstein, C. (1991) *Nature (London)* **349**, 293–299.
4. Mottez, E., Jaulin, C., Godeau, F., Choppin, J., Levy, J. P. & Kourilsky, P. (1991) *Eur. J. Immunol.* **21**, 467–471.
5. Falk, K., Rötzschke, O., Stevanovic, S., Jung, G. & Rammensee, H. G. (1991) *Nature (London)* **351**, 290–296.
6. Falk, K., Rötzschke, O., Deres, K., Metzger, J., Jung, G. & Rammensee, H. G. (1991) *J. Exp. Med.* **174**, 425–434.
7. Tarleton, R. L., Koller, B. H., Latour, A. & Postan, M. (1992) *Nature (London)* **356**, 338–340.
8. Van Bleek, G. M. & Nathenson, S. G. (1990) *Nature (London)* **348**, 213–216.
9. Rötzschke, O., Falk, K., Deres, K., Schild, H., Norda, M., Metzger, J., Jung, G. & Rammensee, H. G. (1990) *Nature (London)* **348**, 252–254.
10. Williams, D. B., Barber, B. H., Flavell, R. A. & Allen, H. (1989) *J. Immunol.* **142**, 2796–2806.
11. Townsend, A. R. M., Bastin, J., Gould, K. & Brownlee, G. G. (1986) *Nature (London)* **324**, 575–577.
12. Krangel, M. S.; Orr, H. T. & Strominger, J. L. (1979) *Cell* **18**, 979–991.
13. Townsend, A., Elliott, T., Cerundolo, V., Foster, L., Barber, B. & Tse, A. (1990) *Cell* **62**, 285–295.
14. Kozlowski, S., Takeshita, T., Boehncke, W.-H., Takahashi, H., Boyd, L. F., Germain, R. N., Berzofsky, J. A. & Margulies, D. H. (1991) *Nature (London)* **349**, 74–77.
15. Rock, K. L., Rothstein, L. E., Gamble, S. R. & Benacerraf, B. (1990) *Proc. Natl. Acad. Sci. USA* **87**, 7517–7521.
16. Rock, K. L., Gamble, S., Rothstein, L. & Benacerraf, B. (1991) *Proc. Natl. Acad. Sci. USA* **88**, 301–304.
17. Vitiello, A., Potter, T. A. & Sherman, L. A. (1990) *Science* **250**, 1423–1426.
18. Boyd, L. F., Kozlowski, S. & Margulies, D. H. (1992) *Proc. Natl. Acad. Sci. USA* **89**, 2242–2246.
19. Allen, H., Fraser, J., Flyer, D., Calvin, S. & Flavell, R. (1986) *Proc. Natl. Acad. Sci. USA* **83**, 7447–7451.
20. Rock, K. L., Gramm, C. & Benacerraf, B. (1991) *Proc. Natl. Acad. Sci. USA* **88**, 4200–4204.
21. Hansen, T. H., Myers, N. B. & Lee, D. R. (1988) *J. Immunol.* **140**, 3522–3527.
22. Otten, G. R., Bikoff, E., Ribaldo, R. K., Kozlowski, S., Margulies, D. H. & Germain, R. N. (1992) *J. Immunol.* **148**, 3723–3732.
23. Koller, B. H. & Smithies, O. (1989) *Proc. Natl. Acad. Sci. USA* **86**, 8932–8935.
24. Elliott, T. (1991) *Immunol. Today* **12**, 386–388.
25. Elliott, T., Cerundolo, V., Elvin, J. & Townsend, A. (1991) *Nature (London)* **351**, 402–406.
26. Evans, G. A., Margulies, D. H., Shykind, B., Seidman, J. G. & Ozato, K. (1982) *Nature (London)* **300**, 755–757.
27. McCluskey, J., Boyd, L., Foo, M., Forman, J., Margulies, D. H. & Bluestone, J. A. (1986) *J. Immunol.* **137**, 3881–3890.
28. Saper, M. A., Bjorkman, P. J. & Wiley, D. C. (1991) *J. Mol. Biol.* **219**, 277–319.
29. Chaudhary, V. K., Queen, C., Junghans, R. P., Waldmann, T. A., Fitzgerald, D. J. & Pastan, I. (1989) *Nature (London)* **339**, 394–397.
30. Horton, R. M., Hunt, H. D., Ho, S. N., Pullen, J. K. & Pease, L. R. (1989) *Gene* **77**, 61–68.
31. Gunning, P., Leavitt, J., Muscat, G., Ng, S.-Y. & Kedes, L. (1987) *Proc. Natl. Acad. Sci. USA* **84**, 4831–4835.
32. Margulies, D. H., Evans, G. A., Ozato, K., Camerini-Otero, R. D., Tanaka, K., Appella, E. & Seidman, J. G. (1983) *J. Immunol.* **130**, 463–470.
33. Margulies, D. H., Ramsey, A. L., Boyd, L. F. & McCluskey, J. (1986) *Proc. Natl. Acad. Sci. USA* **83**, 5252–5256.
34. Shirai, M., Pendleton, C. D. & Berzofsky, J. A. (1992) *J. Immunol.* **148**, 1657–1667.
35. Ljunggren, H. G., Stam, N. J., Ohlen, C., Neefjes, J. J., Hoglund, P., Heemels, M. T., Bastin, J., Schumacher, T. N. M., Townsend, A., Karre, K. & Ploegh, H. (1990) *Nature (London)* **346**, 476–480.
36. Reddehase, M. J., Rothbard, J. B. & Koszinowski, U. H. (1989) *Nature (London)* **337**, 651–653.
37. Godeau, F., Casanova, J.-L., Luescher, I. F., Fairchild, K. D., Delabre, C., Saucier, C., Gachelin, G. & Kourilsky, P. (1992) *Int. Immunol.* **4**, 265–275.
38. Parker, K. C., Silver, M. L. & Wiley, D. C. (1992) *Mol. Immunol.* **29**, 371–378.
39. Garboczi, D. N., Hung, D. T. & Wiley, D. C. (1992) *Proc. Natl. Acad. Sci. USA* **89**, 3429–3433.
40. Silver, M. L., Parker, K. C. & Wiley, D. C. (1991) *Nature (London)* **350**, 619–622.



PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books

Search [PubMed] for

Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation

Matcher

Batch Citation

Matcher

Clinical Queries

LinkOut

Cubby

Related

Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

[1]: J Med Chem. 1994 Jun 24;37(13):1991-5.

Related Articles, Links

Synthesis and characterization of selective fluorescent ligands for the neurokinin NK2 receptor.

Bradshaw CG, Ceszkowski K, Turcatti G, Beresford IJ, Chollet A.

Glaxo Institute for Molecular Biology, Geneve, Switzerland.

Several fluorescent probes for the NK2 receptor were designed, synthesized, and pharmacologically characterized. These fluorescent ligands are analogues of the selective NK2 heptapeptide antagonist N-alpha-benzoyl-Ala-Ala-D-Trp-Phe-D-Pro-Pro-Nle-NH₂ (1, GR94800). They were obtained by substitution of 2,n-diaminoalkyl amino acid (n = 3-6) for Ala1 and the subsequent coupling of the fluorophore NBD (7-nitrobenz-2-oxa-1,3-diazol-4-yl) or fluorescein thiocarbamyl to the N-omega amino group. The fluorescent derivatives retained high binding affinities for the NK2 receptor in transfected CHO cells. In contrast, fluorescent derivatives made by replacing the N-alpha-benzoyl group of 1 by NBD or fluorescein were considerably less active. The effect on ligand potency of varying the length of the spacer arm between the peptide moiety and the fluorescent group was also studied. The most potent fluorescent antagonists were N-alpha-benzoyl-Dab(gamma-NBD)-Ala-D-Trp-Phe-D-Pro-Pro-Nle-NH₂ (5B), pKi = 8.87 for NK2; N-alpha-benzoyl-Orn (delta-NBD)-Ala-D-Trp-Phe-D-Pro-Pro-Nle-NH₂ (4B), pKi = 8.84; and N-alpha-benzoyl-Lys(epsilon-NBD)-Ala-D-Trp-Phe-D-Pro-Pro-Nle-NH₂ (3B), pKi = 8.83. These three compounds were highly selective for NK2 over NK3 and NK1 receptors. We show that these fluorescent ligands are useful tools for the detection of NK2 receptor expression by flow cytometry. Additionally, these fluorescent probes should prove valuable for fluorescence microscopy and study of ligand-receptor interaction by spectrofluorimetry.

PMID: 8027981 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort

[Write to the Help Desk](#)



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Books

Search for Limits

Preview/Index

History

Clipboard

Details

About Entrez

Show: 20 Sort

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation

Matcher

Batch Citation

Matcher

Clinical Queries

LinkOut

Cubby

Related**Resources**

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

1: Farmaco. 1994 Feb;49(2):83-7.

Related Articles, Links


Synthesis and muscarinic receptors affinity of a series of antagonist bivalent ligands.**Piergentili A, Quaglia W, Tayebati SK, Paparelli F, Malmusi L, Brasili L.**

Dipartimento di Scienze Chimiche, Universita di Camerino.

A series of bivalent ligands (2-8) derived from 2,2-diphenyl-[1,3]-dioxolan-4-ylmethyl-dimethylamine methiodide 1 has been synthesized and tested to evaluate affinity and selectivity for M₁, M₂ and M₃ muscarinic receptor subtypes. In order to study the contribution of the spacer and of a second cationic head to the binding process, unsymmetrical ligands (9,10) have also been prepared. The results, expressed in terms of pA₂ values, show that, although the spacer negatively affects the interaction of the bivalent ligands with the three receptor subtypes, affinity and selectivity are modulated by its length; this indicates that the pharmacophore binding sites are organized differently with respect to their mutual proximity and orientation, in each receptor subtype.

PMID: 7516166 [PubMed - indexed for MEDLINE]Show: 20 Sort [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Freedom of Information Act](#) | [Disclaimer](#)

Aug 6 2003 12:56:11



PH8

[PubMed](#) [Nucleotide](#) [Protein](#) [Genome](#) [Structure](#) [PMC](#) [Taxonomy](#) [OMIM](#) [Books](#)

Search for

Limits [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)

[About Entrez](#)

Show: Sort

[Text Version](#)

[Entrez PubMed](#)

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

[PubMed Services](#)

[Journals Database](#)

[MeSH Database](#)

[Single Citation](#)

[Matcher](#)

[Batch Citation](#)

[Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[Cubby](#)

[Related](#)

[Resources](#)

[Order Documents](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

[Privacy Policy](#)

1: Acta Pathol Microbiol Immunol Scand [C]. 1986 Dec;94(6):227-31.

[Related Articles](#),
[Links](#)

An enzyme-linked-immunosorbent assay method for detection of immunoglobulins to pertussis toxin.

Zackrisson G, Lagergard T, Lonnroth I.

A microplate enzyme-linked-immunosorbent assay (ELISA) for detection of antibodies against pertussis toxin, using fetuin as a spacer-layer between the solid phase and pertussis toxin, was compared to a method using pertussis toxin alone as antigen. Antibodies of IgG, IgM and IgA classes were studied in paired human sera. Raised antibody levels were demonstrated for ten children suffering from whooping cough. Antibody levels in sera from 20 healthy 4-year-old children showed high correlation to earlier experienced pertussis. No significant antibody titer changes against pertussis toxin were seen in children with adenovirus infection. The investigation shows that precoating with fetuin improves the sensitivity of the method as much as 5-30 times and makes the method useful in serological diagnosis of whooping cough.

PMID: 2437765 [PubMed - indexed for MEDLINE]

Show: Sort

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)

Aug 6 2003 12:56:11



PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books

Search for

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation

Matcher

Batch Citation

Matcher

Clinical Queries

LinkOut

Cubby

Related

Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

1: Arch Toxicol. 1989;63(6):462-8.

Related Articles, Links

Development of an ELISA for detection of an organophosphorus compound using monoclonal antibodies.

Erhard MH, Schmidt P, Kuhlmann R, Losch U.

Institut fur Physiologie, Universitat Munchen, Federal Republic of Germany.

This paper describes a specific and highly sensitive ELISA system using monoclonal antibodies in order to assay an organophosphorus compound. The soman derivative methyl phosphonic acid, p-aminophenyl 1,2,2,-trimethyl-propyl diester (MATP) served as model substance. In order to obtain antibody-producing hybridomas BALB/c mice were immunized with MATP linked onto human serum albumin (HSA). The spleen cells of immunized mice were fused with syngenic plasmacytomas of the non-producer-line X63Ag8.653 with the aid of polyethylene glycol. To eliminate undesirable cross-reaction, common screening procedures were modified by directly coating the ELISA plates with hapten. Five out of 15 positive cell-lines were cloned by limiting dilution and further propagated. The respective immunoglobulin class and subclass of the obtained monoclonal antibodies was determined. Four of which were identified as IgG1, the other as IgG2a. After enrichment of antibodies in ascites and their isolation by protein A-sepharose, the affinity of various monoclonal antibodies was estimated in competitive inhibition enzyme immunoassay (CIEIA) by measuring the IC₅₀ rates of free MATP. The rates were found to lie between 2.5 x 10(-6) mol/l and 4.3 x 10(-4) mol/l MATP. The IC₁₀ rate for detectable MATP concentration was 5.4 x 10(-7) mol/l MATP. Test duration was 280 min. The reactivity of the monoclonal antibodies with structurally related substances was used to check their specificity. Cross-reaction turned out to be negative. In order to develop a direct competitive ELISA, MATP was linked to horse radish peroxidase (HRPO) by adding a spacer. This helped to reduce total duration to 40 min.(ABSTRACT TRUNCATED AT 250 WORDS)

PMID: 2695015 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Text



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Books

Search 

for



Limits

Preview/Index

History

Clipboard

Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation

Matcher

Batch Citation

Matcher

Clinical Queries

LinkOut

Cubby

Related

Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

 Display

 Abstract


Show: 20



Sort



Send to:



Text



1: J Immunol. 1993 Mar 1;150(5):1794-803.

Related Articles, Links

Mapping epitopes of human Fc gamma RII (CDw32) with monoclonal antibodies and recombinant receptors.

Ierino FL, Hulett MD, McKenzie IF, Hogarth PM.

Austin Research Institute, Austin Hospital, Heidelberg, Victoria, Australia.

Fc gamma RII is a low affinity FcR for IgG with two Ig-like extracellular domains (D1 gamma and D2 gamma), a transmembrane domain, and a cytoplasmic domain. The production, characterization, and epitope analysis of four anti-human Fc gamma RII mAb (8.2, 8.7, 8.26, and 7.30) are detailed, and the mAb are compared with two defined CDw32 mAb, IV.3 and CIKM5. Reactivity of all mAb with Fc gamma RII was demonstrated by (a) specific binding to Fc gamma RII+ L cells (produced after transfection of L cells with human Fc gamma RIIa cDNA, HFc3.0), by using flow cytometry, (b) inhibition of the binding of SRBC sensitized with rabbit antibody (EA) to Fc gamma RII+ L cells, and (c) immunoprecipitation and SDS-PAGE, which detected a 42-kDa protein on K562 and U937 cells and a single 45-kDa protein on Fc gamma RII+ L cells. The mAb were able to detect different forms of Fc gamma RII, by flow cytometry, on Daudi cells (8.7 and 7.30) and U937 cells (8.2, IV.3, and CIKM5); 8.26 stained Daudi cells with intermediate fluorescence and U937 cells with the highest fluorescence, relative to the remaining mAb. Binding to transiently expressed isoforms of Fc gamma RII (a and b1) and four allelic variants of Fc gamma RIIa in COS-7 cells did not distinguish the mAb epitopes. Further mapping of the mAb epitopes was determined by (a) EA inhibition assays, (b) mAb blocking studies, and (c) the binding of the mAb to segments of human Fc gamma RIIa by using genetically engineered chimeric receptors. Chimeric receptors expressing either D1 gamma linked to domain 2 of Fc epsilon RI or domain 1 of Fc epsilon RI linked to D2 gamma were produced by exchanging homologous, but antigenically different, regions of Fc gamma RIIa and the high affinity receptor for IgE. Four clusters of mAb were identified, each mapping to discrete epitopes of Fc gamma RII. Cluster I (mAb 8.2 and CIKM5) defines a combinatorial epitope with determinants in D1 gamma and D2 gamma distant from the IgG Fc binding site, inasmuch as F(ab')2 fragments of 8.2 and CIKM5 do not inhibit the binding of EA to Fc gamma RII. The epitopes of clusters 2 (mAb 8.26), 3 (mAb IV.3), and 4 (mAb 8.7 and 7.30) are located entirely in D2 gamma and all involve the

IgG Fc binding region, because F(ab')/F(ab')2 fragments of the mAb inhibit EA binding to Fc gamma RII. Thus, all mAb that inhibit the binding of EA map totally to D2 gamma; it is likely the IgG Fc binding region is also contained in D2 gamma.

PMID: 7679695 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)

Aug 6 2003 12:56:11